Bimekizumab for Hidradenitis Suppurativa


featured image

Bimekizumab is in clinical development for the treatment of Hidradenitis Suppurativa (HS) in adults. HS is a painful, long-term skin condition that causes abscesses and scarring on the skin.

Interventions: Bimekizumab (UCB4940)
Therapeutic Areas: Dermatology
Year: 2022

Bimekizumab is in clinical development for the treatment of Hidradenitis Suppurativa (HS) in adults. HS is a painful, long-term skin condition that causes abscesses and scarring on the skin. The exact cause of hidradenitis suppurativa is unknown, but it occurs near hair follicles where there are sweat glands, usually around the groin, bottom, breasts and armpits. Mild to moderate HS has been successfully treated with oral antibiotics, topical therapy, and lifestyle modifications. However, moderate to severe HS is known to be unresponsive to normal treatments. Surgery is an option for severe HS, but it can cause problems for the patient and the disease may still return. There is a need for safe and effective treatments for patients with moderate to severe HS.